 Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University VCU for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission. 